论文部分内容阅读
目的探讨地塞米松(DXM)对热性惊厥(FS)患儿外周血单个核细胞(PBMC)细胞间黏附分子-1(ICAM-1)及配体淋巴细胞功能相关抗原-1(LFA-1)表达和分泌的影响。方法 FS组患儿16例分为FS对照组和DXM干预组,DXM干预组采用1.0μmol.L-1的DXM进行干预;健康对照组16例,为年龄和性别与FS组患儿相匹配的同期体检健康儿童。常规方法进行FS组和健康对照组的PBMC培养。采用流式细胞仪检测PBMC表面ICAM-1、LFA-1表达水平;采用ELISA法检测培养上清中ICAM-1、LFA-1水平。结果 FS对照组在体外培养的PBMC表面ICAM-1、LFA-1表达水平分别为(19.78±8.93)%和(43.05±15.85)%,明显高于健康对照组[(13.88±6.73)%,(30.43±16.25)%](Pa<0.05);DXM干预组的PBMC表面ICAM-1、LFA-1表达水平分别为(17.14±7.98)%和(33.93±19.76)%,与FS对照组比较有下调趋势,但差异无统计学意义(Pa>0.05)。FS对照组PBMC的ICAM-1、LFA-1分泌水平分别为(6.73±3.88)%和(4.84±2.95)%,明显高于健康对照组[(4.24±2.42)%,(2.76±1.36)%](Pa<0.05);DXM干预组PBMC的ICAM-1、LFA-1分泌水平[(4.34±1.82)%,(3.06±2.81)%]明显低于FS对照组(Pa<0.05)。结论糖皮质激素DXM干预后ICAM-1、LFA-1的表达被抑制,抑制FS患儿ICAM-1、LFA-1的高表达可作为其治疗的新靶点。
Objective To investigate the effects of dexamethasone (DXM) on the expression of intercellular adhesion molecule-1 (ICAM-1) in peripheral blood mononuclear cells (PBMCs) and ligand-associated lymphocyte functional antigen-1 ) Expression and secretion. Methods 16 cases of FS group were divided into FS control group and DXM intervention group. DXM intervention group was treated with 1.0 μmol·L-1 DXM. Sixteen healthy control subjects were matched for age and sex with those of FS group Physical examination of healthy children over the same period. Conventional methods were used to culture PBMC from healthy donors. The expression of ICAM-1 and LFA-1 on the surface of PBMC was detected by flow cytometry. The levels of ICAM-1 and LFA-1 in the culture supernatant were detected by ELISA. Results The expression levels of ICAM-1 and LFA-1 in PBMC of FS control group were (19.78 ± 8.93)% and (43.05 ± 15.85)%, respectively, which were significantly higher than that of healthy control group [(13.88 ± 6.73)% vs 30.43 ± 16.25)%] (P <0.05). The expression levels of ICAM-1 and LFA-1 on the surface of PBMC of DXM intervention group were (17.14 ± 7.98)% and (33.93 ± 19.76)%, respectively, Trend, but the difference was not statistically significant (Pa> 0.05). The secretion levels of ICAM-1 and LFA-1 in PBMC of FS control group were (6.73 ± 3.88)% and (4.84 ± 2.95)%, respectively, which were significantly higher than that of healthy control group [(4.24 ± 2.42)% and (2.76 ± 1.36)% ] (P <0.05). The levels of ICAM-1 and LFA-1 secreted by PBMC in DXM-treated group were significantly lower than those in FS control group (4.34 ± 1.82% vs 3.06 ± 2.81%, P <0.05). Conclusions The expression of ICAM-1 and LFA-1 is inhibited after glucocorticoid DXM intervention. Inhibition of high expression of ICAM-1 and LFA-1 in children with FS may be a new therapeutic target.